Superseded Local Coverage Article Billing and Coding

Billing and Coding: Nivolumab

A54862

Expand All | Collapse All
Superseded
To see the currently-in-effect version of this document, go to the section.

Contractor Information

Article Information

General Information

Article ID
A54862
Article Title
Billing and Coding: Nivolumab
Article Type
Billing and Coding
Original Effective Date
04/01/2016
Revision Effective Date
04/01/2022
Revision Ending Date
06/30/2022
Retirement Date
N/A
AMA CPT / ADA CDT / AHA NUBC Copyright Statement

CPT codes, descriptions and other data only are copyright 2022 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Current Dental Terminology © 2022 American Dental Association. All rights reserved.

Copyright © 2022, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the American Hospital Association (AHA) copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312‐893‐6816.

Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.

CMS National Coverage Policy

N/A

Article Guidance

Article Text

Abstract:

This article contains billing and coding guidelines that complement the Local Coverage Determination (LCD) Drugs and Biologicals, Coverage of, for Label and Off-Label Uses.

Utilization Guidelines:
Dose and frequency should be in accordance with the FDA label or recognized compendia (for off-label uses). When services are performed in excess of established parameters, they may be subject to review for medical necessity.

If the disease progressed while receiving another PD-1 directed agent (for example, pembrolizumab), the use of nivolumab is not considered reasonable/necessary. If the PD-1 directed agent was discontinued for reasons other than disease progression, then nivolumab may be used when an approved indication is met.

Coding Information:

When billing for metastatic (secondary) disease, only use the code for the primary malignancy if still present, and only use the related “personal history of” Z code if not.

HCPCS code J9299 should be used to report nivolumab for the Part A and B MAC.

Administration of nivolumab may be billed using the chemotherapy administration code 96413 (Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug) and 96415 (each additional hour (List separately in addition to code for primary procedure) when required due to infusion related adverse reactions in adults (up to 2 hours total) or when used in pediatric aged Medicare beneficiaries (up to 4 hours total).

FDA and Compendia Review:

Clinical Pharmacology website http://www.clinicalpharmacology.com/. Accessed 03/08/2022.
FDA label for Opdivo (nivolumab). FDA website http://www.accessdata.fda.gov/scripts/cder/drugsatfda.
Lexi-Drugs Web site. http://online.lexi.com. Accessed 03/08/2022.
Micromedex DrugDex® Web site. http://www.micromedexsolutions.com/home/dispatch. Accessed 03/08/2022.
National Comprehensive Cancer Network website http://www.nccn.org/index.asp. Accessed 03/08/2022.

Coding Information

CPT/HCPCS Codes

Group 1

(1 Code)
Group 1 Paragraph

N/A

Group 1 Codes
CodeDescription
J9299 INJECTION, NIVOLUMAB, 1 MG

CPT/HCPCS Modifiers

N/A

ICD-10-CM Codes that Support Medical Necessity

Group 1

(315 Codes)
Group 1 Paragraph

NOTE: ICD-10-CM code C68.0 – malignant neoplasm of urethra should be used to indicate urothelial carcinoma of the prostate

Group 1 Codes
CodeDescription
C00.0 - C00.6 Malignant neoplasm of external upper lip - Malignant neoplasm of commissure of lip, unspecified
C00.8 Malignant neoplasm of overlapping sites of lip
C01 Malignant neoplasm of base of tongue
C02.0 - C02.4 Malignant neoplasm of dorsal surface of tongue - Malignant neoplasm of lingual tonsil
C02.8 Malignant neoplasm of overlapping sites of tongue
C02.9 Malignant neoplasm of tongue, unspecified
C03.0 Malignant neoplasm of upper gum
C03.1 Malignant neoplasm of lower gum
C03.9 Malignant neoplasm of gum, unspecified
C04.0 Malignant neoplasm of anterior floor of mouth
C04.1 Malignant neoplasm of lateral floor of mouth
C04.8 Malignant neoplasm of overlapping sites of floor of mouth
C04.9 Malignant neoplasm of floor of mouth, unspecified
C05.0 Malignant neoplasm of hard palate
C05.1 Malignant neoplasm of soft palate
C05.8 Malignant neoplasm of overlapping sites of palate
C06.0 Malignant neoplasm of cheek mucosa
C06.2 Malignant neoplasm of retromolar area
C06.80 Malignant neoplasm of overlapping sites of unspecified parts of mouth
C06.89 Malignant neoplasm of overlapping sites of other parts of mouth
C06.9 Malignant neoplasm of mouth, unspecified
C09.0 Malignant neoplasm of tonsillar fossa
C09.1 Malignant neoplasm of tonsillar pillar (anterior) (posterior)
C09.8 Malignant neoplasm of overlapping sites of tonsil
C09.9 Malignant neoplasm of tonsil, unspecified
C10.0 Malignant neoplasm of vallecula
C10.1 Malignant neoplasm of anterior surface of epiglottis
C10.2 Malignant neoplasm of lateral wall of oropharynx
C10.3 Malignant neoplasm of posterior wall of oropharynx
C10.4 Malignant neoplasm of branchial cleft
C10.8 Malignant neoplasm of overlapping sites of oropharynx
C11.0 - C11.3 Malignant neoplasm of superior wall of nasopharynx - Malignant neoplasm of anterior wall of nasopharynx
C11.8 Malignant neoplasm of overlapping sites of nasopharynx
C11.9 Malignant neoplasm of nasopharynx, unspecified
C12 Malignant neoplasm of pyriform sinus
C13.0 - C13.2 Malignant neoplasm of postcricoid region - Malignant neoplasm of posterior wall of hypopharynx
C13.8 Malignant neoplasm of overlapping sites of hypopharynx
C13.9 Malignant neoplasm of hypopharynx, unspecified
C14.0 Malignant neoplasm of pharynx, unspecified
C14.2 Malignant neoplasm of Waldeyer's ring
C14.8 Malignant neoplasm of overlapping sites of lip, oral cavity and pharynx
C15.3 Malignant neoplasm of upper third of esophagus
C15.4 Malignant neoplasm of middle third of esophagus
C15.5 Malignant neoplasm of lower third of esophagus
C15.8 Malignant neoplasm of overlapping sites of esophagus
C16.0 Malignant neoplasm of cardia
C16.1 Malignant neoplasm of fundus of stomach
C16.2 Malignant neoplasm of body of stomach
C16.3 Malignant neoplasm of pyloric antrum
C16.4 Malignant neoplasm of pylorus
C16.5 Malignant neoplasm of lesser curvature of stomach, unspecified
C16.6 Malignant neoplasm of greater curvature of stomach, unspecified
C16.8 Malignant neoplasm of overlapping sites of stomach
C17.0 - C17.3 Malignant neoplasm of duodenum - Meckel's diverticulum, malignant
C17.8 - C17.9 Malignant neoplasm of overlapping sites of small intestine - Malignant neoplasm of small intestine, unspecified
C18.0 - C18.9 Malignant neoplasm of cecum - Malignant neoplasm of colon, unspecified
C19 Malignant neoplasm of rectosigmoid junction
C20 Malignant neoplasm of rectum
C21.1 Malignant neoplasm of anal canal
C21.2 Malignant neoplasm of cloacogenic zone
C21.8 Malignant neoplasm of overlapping sites of rectum, anus and anal canal
C22.0 Liver cell carcinoma
C22.8 Malignant neoplasm of liver, primary, unspecified as to type
C24.1 Malignant neoplasm of ampulla of Vater
C30.0 Malignant neoplasm of nasal cavity
C31.0 Malignant neoplasm of maxillary sinus
C31.1 Malignant neoplasm of ethmoidal sinus
C32.0 - C32.3 Malignant neoplasm of glottis - Malignant neoplasm of laryngeal cartilage
C32.8 Malignant neoplasm of overlapping sites of larynx
C32.9 Malignant neoplasm of larynx, unspecified
C33 Malignant neoplasm of trachea
C34.00 - C34.92 Malignant neoplasm of unspecified main bronchus - Malignant neoplasm of unspecified part of left bronchus or lung
C38.4 Malignant neoplasm of pleura
C43.0 - C43.9 Malignant melanoma of lip - Malignant melanoma of skin, unspecified
C4A.0 Merkel cell carcinoma of lip
C4A.111 Merkel cell carcinoma of right upper eyelid, including canthus
C4A.112 Merkel cell carcinoma of right lower eyelid, including canthus
C4A.121 Merkel cell carcinoma of left upper eyelid, including canthus
C4A.122 Merkel cell carcinoma of left lower eyelid, including canthus
C4A.21 - C4A.22 Merkel cell carcinoma of right ear and external auricular canal - Merkel cell carcinoma of left ear and external auricular canal
C4A.31 Merkel cell carcinoma of nose
C4A.39 Merkel cell carcinoma of other parts of face
C4A.4 Merkel cell carcinoma of scalp and neck
C4A.51 Merkel cell carcinoma of anal skin
C4A.52 Merkel cell carcinoma of skin of breast
C4A.59 Merkel cell carcinoma of other part of trunk
C4A.61 - C4A.62 Merkel cell carcinoma of right upper limb, including shoulder - Merkel cell carcinoma of left upper limb, including shoulder
C4A.71 - C4A.72 Merkel cell carcinoma of right lower limb, including hip - Merkel cell carcinoma of left lower limb, including hip
C4A.8 Merkel cell carcinoma of overlapping sites
C44.00 Unspecified malignant neoplasm of skin of lip
C44.02 Squamous cell carcinoma of skin of lip
C44.09 Other specified malignant neoplasm of skin of lip
C45.0 Mesothelioma of pleura
C45.1 Mesothelioma of peritoneum
C45.2 Mesothelioma of pericardium
C45.7 Mesothelioma of other sites
C51.0 - C51.2 Malignant neoplasm of labium majus - Malignant neoplasm of clitoris
C51.8 Malignant neoplasm of overlapping sites of vulva
C53.0 Malignant neoplasm of endocervix
C53.1 Malignant neoplasm of exocervix
C53.8 Malignant neoplasm of overlapping sites of cervix uteri
C54.0 - C54.3 Malignant neoplasm of isthmus uteri - Malignant neoplasm of fundus uteri
C54.8 Malignant neoplasm of overlapping sites of corpus uteri
C63.2 Malignant neoplasm of scrotum
C64.1 - C64.9 Malignant neoplasm of right kidney, except renal pelvis - Malignant neoplasm of unspecified kidney, except renal pelvis
C65.1 - C65.9 Malignant neoplasm of right renal pelvis - Malignant neoplasm of unspecified renal pelvis
C66.1 Malignant neoplasm of right ureter
C66.2 Malignant neoplasm of left ureter
C66.9 Malignant neoplasm of unspecified ureter
C67.0 - C67.9 Malignant neoplasm of trigone of bladder - Malignant neoplasm of bladder, unspecified
C68.0 Malignant neoplasm of urethra
C69.31 - C69.32 Malignant neoplasm of right choroid - Malignant neoplasm of left choroid
C69.41 - C69.42 Malignant neoplasm of right ciliary body - Malignant neoplasm of left ciliary body
C69.61 Malignant neoplasm of right orbit
C69.62 Malignant neoplasm of left orbit
C69.90 - C69.92 Malignant neoplasm of unspecified site of unspecified eye - Malignant neoplasm of unspecified site of left eye
C7A.1 Malignant poorly differentiated neuroendocrine tumors
C76.0 Malignant neoplasm of head, face and neck
C81.10 - C81.49 Nodular sclerosis Hodgkin lymphoma, unspecified site - Lymphocyte-rich Hodgkin lymphoma, extranodal and solid organ sites
C81.71 - C81.79 Other Hodgkin lymphoma, lymph nodes of head, face, and neck - Other Hodgkin lymphoma, extranodal and solid organ sites
C81.90 - C81.99 Hodgkin lymphoma, unspecified, unspecified site - Hodgkin lymphoma, unspecified, extranodal and solid organ sites
C84.Z1 Other mature T/NK-cell lymphomas, lymph nodes of head, face, and neck
C84.Z2 Other mature T/NK-cell lymphomas, intrathoracic lymph nodes
C84.Z3 Other mature T/NK-cell lymphomas, intra-abdominal lymph nodes
C84.Z4 Other mature T/NK-cell lymphomas, lymph nodes of axilla and upper limb
C84.Z5 Other mature T/NK-cell lymphomas, lymph nodes of inguinal region and lower limb
C84.Z6 Other mature T/NK-cell lymphomas, intrapelvic lymph nodes
C84.Z7 Other mature T/NK-cell lymphomas, spleen
C84.Z8 Other mature T/NK-cell lymphomas, lymph nodes of multiple sites
C84.Z9 Other mature T/NK-cell lymphomas, extranodal and solid organ sites
C84.91 - C84.99 Mature T/NK-cell lymphomas, unspecified, lymph nodes of head, face, and neck - Mature T/NK-cell lymphomas, unspecified, extranodal and solid organ sites
C86.0 Extranodal NK/T-cell lymphoma, nasal type
D09.0 Carcinoma in situ of bladder
D37.01 Neoplasm of uncertain behavior of lip
D37.02 Neoplasm of uncertain behavior of tongue
D37.05 Neoplasm of uncertain behavior of pharynx
D37.09 Neoplasm of uncertain behavior of other specified sites of the oral cavity
D37.1 Neoplasm of uncertain behavior of stomach
D37.8 Neoplasm of uncertain behavior of other specified digestive organs
D38.0 Neoplasm of uncertain behavior of larynx
D38.5 Neoplasm of uncertain behavior of other respiratory organs
D38.6 Neoplasm of uncertain behavior of respiratory organ, unspecified
Z85.01 Personal history of malignant neoplasm of esophagus
Z85.038 Personal history of other malignant neoplasm of large intestine
Z85.118 Personal history of other malignant neoplasm of bronchus and lung
Z85.21 Personal history of malignant neoplasm of larynx
Z85.22 Personal history of malignant neoplasm of nasal cavities, middle ear, and accessory sinuses
Z85.51 Personal history of malignant neoplasm of bladder
Z85.528 Personal history of other malignant neoplasm of kidney
Z85.59 Personal history of malignant neoplasm of other urinary tract organ
Z85.71 Personal history of Hodgkin lymphoma
Z85.810 Personal history of malignant neoplasm of tongue
Z85.818 Personal history of malignant neoplasm of other sites of lip, oral cavity, and pharynx
Z85.819 Personal history of malignant neoplasm of unspecified site of lip, oral cavity, and pharynx
Z85.820 Personal history of malignant melanoma of skin
Z85.821 Personal history of Merkel cell carcinoma
Z85.840 Personal history of malignant neoplasm of eye

ICD-10-CM Codes that DO NOT Support Medical Necessity

N/A

ICD-10-PCS Codes

N/A

Additional ICD-10 Information

N/A

Bill Type Codes

Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the article does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the article should be assumed to apply equally to all claims.

N/A

Revenue Codes

Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the article, services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the article should be assumed to apply equally to all Revenue Codes.

N/A

Other Coding Information

N/A

Revision History Information

Revision History DateRevision History NumberRevision History Explanation
04/01/2022 R24

Based on compendia review, ICD-10 code C45.1, C45.2 and C45.7 have been added to Group 1 ICD-10 code list effective for dates of service on or after 04/01/2022.

01/01/2022 R23

Based on compendia review, ICD-10 codes C53.0, C53.1 and C53.8 have been added effective for dates of service on or after 01/01/2022.

04/01/2021 R22

Based on provider comment and compendia review, ICD-10 codes C05.8, C10.0, C10.1, C10.2, C10.4, C10.8, C16.1, C16.2, C16.3, C16.4, C16.5, C16.6, C16.8, C17.3, C24.1, C63.2 and D37.1 have been added effective for dates of service on or after 04/01/2021.

01/01/2021 R21

Based on compendia review, ICD-10 codes C51.0-C51.2, C51.8, C54.0-C54.3, C54.8 and C84.91-C84.99 have been added to the ICD-10 code list effective for dates of service on or after 1/1/2021.

10/01/2020 R20

Based on FDA and Compendia review, ICD-10-CM codes C15.3, C15.4, C15.5, C15.8, C16.0, D37.8, Z85.01 have been added effective for dates of service on or after 6/10/2020.

05/01/2020 R19

Based on compendia review, ICD-10-CM codes C21.2, C84.Z1-C84.Z9 and C86.0 have been added effective for dates of service on or after 05/01/2020. The last sentence in the “Utilization Guidelines” has been changed to: If the PD-1 directed agent was discontinued for reasons other than disease progression, then nivolumab may be used when an approved indication is met.

11/07/2019 R18

This article was converted to the new Billing and Coding Article format. The Article Text section has been revised to remove the indications which can be found on the FDA Web site and in the approved compendia. The “Sources of Information” has been revised to “FDA and Compendia Review.” Sources of information other than the FDA and compendia have been moved to a PDF file attached to LCD L33394. The Bill type codes have been removed from this article. Guidance on these codes is available in the Bill type code section.

08/01/2019 R17

Based on compendia review, ICD-10-CM code C7A.1 has been added effective for dates of service on or after 08/01/2019.

10/01/2018 R16

Article revised for annual ICD-10-CM code updates. ICD-10-CM codes C43.11 and C43.12 have been deleted and replaced with ICD-10-CM codes: C43.111, C43.112, C43.121 and C43.122 in code range C43.0 - C43.9 in Group 1 and ICD-10-CM codes C4A.11 and C4A.12 have been deleted and replaced with C4A.111, C4A.112, C4A.121 and C4A.122 in Group 1.

Based on an FDA label update, the following has been added to the “Indications” section of the article:

    Metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy (Effective August 16, 2018 based on (FDA) approval).
07/10/2018 R15

The following indication has been added:

    as a single agent or in combination with ipilimumab for the treatment of adult and pediatric (12 years of age and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin and irinotecan. (Effective 07/10/2018 based on (FDA) approval). 

 

05/10/2018 R14

Indications for intermediate or poor risk, previously untreated advanced renal cell carcinoma, in combination with ipilimumab (Effective April 16, 2018 based on (FDA) approval) and uveal melanoma – metastatic or unresectable disease as a single agent or in combination with ipilimumab have been added to the “Indications” section of the article. 

ICD-10-CM codes C69.61 and C69.62 have been added effective for dates of service on or after 05/10/2018.

03/01/2018 R13

An indication for anal carcinoma - second-line therapy as a single agent for metastatic disease has been added.  ICD-10-CM code C21.1 has been added effective for dates of service on or after 03/01/2018.

The coding information for metastatic malignancy has been revised.

02/01/2018 R12

An indication for adjuvant treatment of melanoma - treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection (Effective December 20, 2017 based on (FDA) approval) and Merkel cell carcinoma have been added. ICD-10-CM codes C4A.0, C4A.11 – C4A.12, C4A.21 – C4A.22, C4A.31, C4A.39, C4A.4, C4A.51, C4A.52, C4A.59, C4A.61-C4A.62, C4A.71-C4A.72, C4A.8, C69.31 – C69.32, C69.41 – C69.42, C81.71 – C81.79, D09.0 and Z85.821 have been added effective for dates of service on or after 02/01/2018. The brand name, Opdivo®, has been removed from the article.

 

09/22/2017 R11

ICD-10-CM code C22.0 has been added for hepatocellular carcinoma effective for dates of service on or after 09/22/2017.

09/22/2017 R10

An indication for hepatocellular carcinoma has been added to the “Indications” section of the article. ICD-10-CM code C22.8 has been added effective for dates of service on or after 09/22/2017.

07/07/2017 R9

An indication for malignant pleural mesothelioma has been added to the “Indications” section of the article. ICD-10-CM codes C38.4 and C45.0 have been added effective for dates of service on or after 07/07/2017.

02/02/2017 R8 An indication for colon cancer has been added to the “Indications” section of the article. The following indication has been added for urothelial carcinoma:
  • Locally advanced or metastatic urothelial carcinoma (Effective 02/02/2017 based on (FDA) approval) who:
    • have disease progression during or following platinum-containing chemotherapy
    • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
  • Bladder cancer:
    • Used as a single agent for clinical stage T4b or T2-4a, N1-3 disease, or for recurrence post cystectomy, or for metastatic disease as subsequent systemic therapy
  • Primary carcinoma of the urethra, upper GU tract tumors, or urothelial carcinoma of the prostate
    • Used as a single agent as subsequent systemic therapy for urrent or metastatic disease
The following ICD-10-CM codes have been added for colon cancer: C17.0-C17.2, C17.8-C17.9, C18.0-C18.9 and Z85.038 effective 02/01/2017. The following ICD-10-CM codes have been added for urothelial carcinoma: C66.1, C66.2, C66.9, C67.0-C67.9, C68.0, Z85.51 and Z85.59 effective for dates of service on or after 02/02/2017. The following NOTE has been added to the Group 1 paragraph in the “Covered ICD-10 Codes” section of the article:
    ICD-10-CM code C68.0 – malignant neoplasm of urethra should be used to indicate urothelial carcinoma of the prostate
02/01/2017 R7 An indication for rectal cancer has been added in the “Indications” section of the article. ICD-10-CM codes C19, C20 and C21.8 have been added to the “Group 1 Codes” list effective 2/1/2017. The following language has been added to the “Utilization” section of the article:
    If the disease progressed while receiving another PD-1 directed agent (for example, pembrolizumab), the use of nivolumab is not considered reasonable/necessary. If the PD-1 directed agent was discontinued for reasons other than disease progression, then nivolumab may be used when an indication above is met.

12/01/2016 R6 An indication for recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy (Effective November 10, 2016 based on (FDA) approval) has been added. The following ICD-10-CM codes have been added effective for dates of service on or after 11/10/2016: C00.0-C00.6, C00.8, C01, C02.0-C02.4, C02.8, C02.9, C03.0, C03.1, C03.9, C04.0, C04.1, C04.8, C04.9, C05.0, C05.1, C06.0, C06.2, C06.80, C06.89, C06.9, C09.0, C09.1, C09.8, C09.9, C10.3, C11.0-C11.3, C11.8, C11.9, C12, C13.0-C13.2, C13.8, C13.9, C14.0, C14.2, C14.8, C30.0, C31.0, C31.1, C32.0-C32.3, C32.8, C32.9, C44.00, C44.02, C44.09, C76.0, D37.01, D37.02, D37.05, D37.09, D38.0, D38.5, D38.6, Z85.21, Z85.22, Z85.810, Z85.818 and Z85.819.
10/01/2016 R5 Corrected language in the second bullet in the "Indications" section to add melanoma:
    BRAF V600 mutation-positive unresectable or metastatic melanoma, as a single agent;

10/01/2016 R4 Effective for dates of service on or after 10/01/2016, the list of Group 2 ICD-10-CM codes has been deleted, ICD-10-CM codes C69.90 – C69.92 have been moved to the list of Group 1 codes and ICD-10-CM code Z85.840 has been added. Based on the annual ICD-10-CM code update, the descriptors were changed for ICD-10-CM codes C81.10 – C81.49.
08/09/2016 R3 The "Indications" have been revised to add: Small cell lung cancer (SCL) - subsequent systemic therapy for patients with performance status 0-2 as a single agent or in combination with ipilimumab for either a) relapse within 6 months following complete or partial response or stable disease with initial treatment or b) primary progressive disease.
05/17/2016 R2 The indications have been revised to add: Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and post-transplantation Adcetris (brentuximab vedotin). (Effective May 17, 2016 based on (FDA) approval). The following ICD-10-CM codes have been added effective for dates of service on or after 05/17/2016: C81.10 – C81.49, C81.90 – C81.99 and Z85.71. ICD-10-CM code Z85.71 has been added to the Group 2 paragraph section.
04/01/2016 R1 The indications have been revised to reflect FDA label updates. Lexi-Drugs compendium has been added to the “Abstract” section of the article and Lexi-Drugs Web site has been added to the “Sources of Information” section.

Associated Documents

Related National Coverage Documents
N/A
Statutory Requirements URLs
N/A
Rules and Regulations URLs
N/A
CMS Manual Explanations URLs
N/A
Other URLs
Public Versions
Updated On Effective Dates Status
10/31/2022 07/01/2022 - 10/31/2022 Retired View
06/24/2022 07/01/2022 - N/A Superseded View
03/25/2022 04/01/2022 - 06/30/2022 Superseded You are here
Some older versions have been archived. Please visit the MCD Archive Site to retrieve them.

Keywords

N/A